Apogee Therapeutics Income Statement (2022-2026) | APGE

Income Statement Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & Cost
Interest income
Interest Income - Total (Quarter) -6.09M-10.31M-9.67M-8.68M-7.84M-7.14M-6.32M-8.73M
Interest expenses
Interest Expenses (Quarter) 6.68M1.32M30.18M115.69M0.05M0.10M61.51M0.04M57.20M43.93M216.17M268.16M
Interest Income - Net (Quarter) -121.78M-10.35M-9.77M-70.19M-7.88M-64.34M-50.25M-224.90M
Operating Items
Research & Development (Quarter) 1.45M9.88M12.21M8.46M13.95M17.07M28.95M28.72M33.21M45.71M60.23M46.39M55.70M54.18M58.44M60.82M
Selling, General & Administrative (Quarter) 0.37M0.62M1.89M4.20M4.94M7.24M8.20M9.46M10.92M12.97M15.65M16.71M17.46M17.10M19.61M21.95M
Operating Expenses (Quarter) 1.82M10.51M14.10M12.66M18.89M24.30M37.16M38.18M44.12M58.69M75.88M63.10M73.17M71.28M78.06M82.77M
Operating Income (Quarter) -1.82M-10.51M-14.10M-12.66M-18.89M-24.30M-37.16M-38.18M-44.12M-58.69M-75.88M-63.10M-73.17M-71.28M-78.06M-82.77M
EBIT (Quarter) -1.82M-10.51M-14.10M-12.66M-18.89M-24.30M-37.16M-38.18M-44.12M-58.69M-75.88M-63.10M-73.17M-71.28M-78.06M-82.77M
Non-operating items
Interest & Investment Income (Quarter) 0.13M3.46M5.42M-0.51M-0.11M9.67M8.68M7.84M-0.39M6.32M8.73M8.74M
Other Non Operating Income (Quarter) -9.15M0.09M0.13M3.46M5.42M6.09M10.31M9.67M8.68M7.84M7.14M6.32M8.73M8.74M
Net income details
EBT (Quarter) -1.82M-10.51M-20.78M-12.53M-18.89M-22.16M-61.91M-32.09M-33.82M-49.02M-67.20M-55.26M-66.02M-64.96M-69.33M-74.03M
Tax Provisions (Quarter) -0.54M0.08M0.07M0.06M-53.88M0.08M
Profit After Tax (Quarter) -1.82M-19.66M-14.01M-12.53M-18.89M-20.84M-31.73M-32.09M-33.82M-49.02M-67.22M-55.34M-66.10M-65.02M-69.30M-74.11M
Income from Continuing Operations (Quarter) -1.82M-10.51M-20.78M-12.53M-18.89M-22.16M-61.91M-32.09M-33.82M-49.02M-66.66M-55.34M-66.10M-65.02M-15.44M-74.11M
Consolidated Net Income (Quarter) -1.82M-10.51M-20.78M-12.53M-18.89M-22.16M-61.91M-32.09M-33.82M-49.02M-66.66M-55.34M-66.10M-65.02M-15.44M-74.11M
Income towards Parent Company (Quarter) -1.82M-10.51M-20.78M-12.53M-18.89M-22.16M-61.91M-32.09M-33.82M-49.02M-66.66M-55.34M-66.10M-65.02M-15.44M-74.11M
Net Income towards Common Stockholders (Quarter) -1.82M-19.66M-14.01M-12.53M-18.89M-20.84M-31.73M-32.09M-33.82M-49.02M-67.22M-55.34M-66.10M-65.02M-69.39M-74.11M
Additional items
EPS (Basic) (Quarter) -1.45-9.46-5.69-2.51-3.78-0.51-1.27-0.64-0.60-0.86-1.22-0.95-1.13-1.11-1.14-1.06
EPS (Diluted) (Quarter) -1.45-9.46-5.69-2.51-3.78-0.51-1.27-0.64-0.60-0.86-1.22-0.95-1.13-1.11-1.14-1.06
Shares Outstanding (Quarter) 1.25M2.08M2.46M5.00M5.00M41.23M25.01M50.19M56.52M56.80M55.19M58.20M58.43M58.77M60.69M69.67M
Shares Outstanding (Diluted) (Quarter) 1.25M2.08M2.46M5.00M5.00M41.23M25.01M50.19M56.52M56.80M55.19M58.20M58.43M58.77M60.69M69.67M
EBITDA (Quarter) -1.82M-10.51M-14.10M-12.66M-18.89M-24.30M-37.16M-38.18M-44.12M-58.69M-75.88M-63.10M-73.17M-71.28M-78.06M-82.77M